Overview

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This trial will be comparing the combination of amiodarone and NAC (n=122) to amiodarone alone and NAC matched placebo (n=122) to determine the rates with which sustained (lasting >30 seconds) or clinically significant POAF is reduced in high risk patients within 7 days after major thoracic surgery.

Phase:

Phase 3

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

The Cleveland Clinic
Vanderbilt University School of Medicine
Washington University School of Medicine

Treatments:

Acetylcysteine
Amiodarone
N-monoacetylcystine